[The pneumococcal vaccine. Its efficacy in patients 55 and over].
Three recent articles are examined in which research using the double-blind randomised clinical trial, the case control study, and the quasi-cohort study is described. Understanding the advantages and disadvantages of these methods makes it easier to grasp the pneumococcal vaccine controversy and make an informed choice.
Unité de médecine familiale, Centre Hospitalier de Verdun.
R
R
Marchand
D000367:Age Factors; D001428:Bacterial Vaccines / Q000592:standards*; D016022:Case-Control Studies; D015331:Cohort Studies; D004311:Double-Blind Method; D006801:Humans; D008875:Middle Aged; D016032:Randomized Controlled Trials as Topic; D012107:Research Design / Q000592:standards*; D013296:Streptococcus pneumoniae / Q000276:immunology*
D001428:Bacterial Vaccines
Le vaccin antipneumococcique. L'efficacité chez les 55 ans et plus.